When she was 21 years old, advocate Samantha Watson was diagnosed with Ewing sarcoma. In this Voices on Cancer post, she describes her journey, how she helps young adults with the financial effects of cancer, and 5 critical qualities for advocates.
Your medications can be more effective—and a whole lot easier to manage—if you follow a few simple guidelines.
Did you know that young adults especially struggle with the financial burdens of cancer care? Samantha Watson and Michelle Landwehr of The Samfund write about the challenges young adults face and what they can do about it.
Oncology professionals from around the world are in Chicago for the ASCO Annual Meeting. There, they will discuss the latest advances and newest thoughts in cancer research. Some of those advances focus on improving the quality of care and patients’ access to it.
Dr. Schapira reflects on costs in cancer treatment and how financial hardship is something that must be considered in the treatment plan.
State of Cancer Care in America: 2016 Report Finds Unprecedented Opportunity Amid Profound Turbulence
Cancer care and treatment are developing quickly but face many obstacles. ASCO President Julie Vose, MD, comments on ASCO’s third annual State of Cancer Care in America report.
Research presented this weekend at the 2016 Cancer Survivorship Symposium will address some of the challenges patients face after treatment ends.
Once you have finished cancer treatment, it is impossible to reconstruct the exact life you had prior to diagnosis. Jennifer Titche talks about the challenges she faces as a young breast cancer survivor and how she is building a life with new goals.
Managing both caregiving and work responsibilities can be difficult. Caregivers can also face potential workplace discrimination or financial issues from taking time off work. Joanna Fawzy Morales, Esq., a cancer rights attorney, talks about the legal protections and practical resources available to help caregivers better navigate work and caregiving.
In January, Randy Hillard was part of the U.S. Food and Drug Administration committee that considered the first application for a “biosimilar” medication. In this guest post, he describes patients’ role in the drug approval process and how the committee’s decision could influence cancer care in the future.